[ad_1]
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said that its scientific founder Dr. Jonathan Kurtis received a new patent for his discovery related to malaria. The patent award could be a milestone in the company’s malaria vaccine program. The company is a medical research innovation incubator that partners with inventors, universities, and research institutes to commercialize discoveries for medical care.
A Novel Approach
Jonathan’s research shows that a third parasite target called PfCDPK-5 has the potential to be used to inhibit the parasite at multiple stages in the malaria cycle. Antibodies to PfCDPK-5 have been found to be effective in preventing merozoites from escaping infected red blood cells and thereby reducing parasite multiplication in the bloodstream.
Previous findings have identified the important role played by the parasite antigens PfGARP and PfSEA in controlling the ability of the malaria parasite to replicate and grow in the human host. PfGARP, or plasmodium falciparum proteins rich in glutamic acididentified as a human antibody target that kills up to 100% of parasites in vitro by inducing apoptosis or parasite programmed cell death.
Ocean Biomedical, Inc. (OCEA) Research Summary
Commenting on the patent, Ocean Biomedical CEO Elizabeth Ng said, “The progress that has been made so far to reach novel targets is a testament to Ocean Biomedical’s innovative model and deep partnership with leading research institutions. We hope that Dr. Kurtis’s discovery will lead to a powerful vaccine that can save hundreds of thousands of lives, and we are proud can help with this important work.
The discovery is important because of the emergence of high-class resistance to artemisinin-based drugs, which are commonly used in the treatment of malaria worldwide, and the situation calls for the development of a new class of antimalarials.
Pipe
Ocean Biomedical’s therapeutic programs focus on oncology, fibrosis, and malaria treatment. The company has a diverse pipeline with various formulations in various stages of development. In oncology, the target is non-small cell lung cancer and glioblastoma multiforme. Studies have shown that an antibody developed by the company against cancer-causing CHI3L1 significantly shrinks tumors.
Read management/analyst commentary on monthly reports
It was also found that the company’s OCF-203 reduces fibrosis by inhibiting Chit1, which could play a key role in research being conducted to find treatments for Idiopathic pulmonary fibrosis and Hermansky-Pudlak Syndrome.
Ocean Biomedical debuted on the stock market on February 15, 2023, through a reverse merger of the special purpose acquisition company Aesther Healthcare Acquisition Corp. The stock began trading on the Nasdaq stock exchange under the ticker symbol OCEA.
[ad_2]
Source link